Last reviewed · How we verify

NCT05695092

Effectiveness of Progressive Muscle Relaxation on Sleep Disturbance in Athletes

Completed NA Last updated 25 August 2023
What this trial tests

NA trial testing Progressive muscle relaxation in Sleep Disturbance in Athletes in 24 participants. Completed in 20 August 2023.

Timeline
23 January 2023
Primary endpoint
20 August 2023
20 August 2023

Quick facts

Lead sponsorRiphah International University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designsingle group
Maskingsingle
Primary purposetreatment
Enrollment24
Start date23 January 2023
Primary completion20 August 2023
Estimated completion20 August 2023
Sites1 location across Pakistan

Drugs / interventions tested

Conditions studied

Sponsor

Riphah International University

Who can join

Adults 18 to 36, any sex, with Sleep Disturbance in Athletes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Literature supports that athletes have so many reasons for sleep disturbance in their day to day practice and during competition. This study is aimed to build familiarity with the significance of sleep for greatest athletic execution as well as providing Progressoive Muscle Relaxation(PMR),(A technique proposed by Jackobson to improve sleep and degrease the anxiety) as strategy to improve sleep prior to a significant competition during tournament

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Progressive muscle relaxation

Trials testing the same drug.

Other Riphah International University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05695092.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing